On my final slide, I want to update you on a key -- on key R&D milestones for the coming 12 months. In terms of regulatory approvals, we await decisions on a number of important new opportunities, including Dupixent in adolescent AG and nasal polyps in Europe. Isatuximab in relapsed-refractory multiple myeloma in the US and Europe, MenQuadfi in the US and Quadrivalent high dose Fluzone in US and Europe. We also have a number of pivotal read out due to -- due, including new molecular entities sutimlimab in cold agglutinin disease and avalglucosidase alfa in Pompe. And lastly, we expect a number of proof-of-concept readouts, this include our third in metastatic breast cancer, sutimlimab in refractory ITP and the Anti-IL33 in COPD.